Niva Bupa Health Insurance Company Limited (NSE:NIVABUPA)
India flag India · Delayed Price · Currency is INR
82.62
-0.26 (-0.31%)
Aug 21, 2026, 3:29 PM IST

Niva Bupa Health Insurance Company Earnings Call Transcripts

Fiscal Year 2027

  • Q1 26/27

    Q1 saw robust growth, with retail health outpacing the industry and profit after tax rising to INR 137.8 crore. Key ratios improved, expense management strengthened, and digital initiatives advanced. Guidance remains for above-market retail growth and stable margins.

Fiscal Year 2026

  • Q4 25/26

    GWP grew 27.4% to INR 9,433 crore with 35% retail growth and profit after tax up 80% year-over-year. Combined ratio improved to 101.4%, and the company targets 25% annual growth, leveraging digital and distribution expansion. Retail health loss ratio improved, and industry initiatives are driving transparency.

  • Q3 25/26

    Strong nine-month growth with PAT up 74% year-over-year and market share gains, supported by robust channel performance and digital initiatives. Industry-wide standardization, GST tailwinds, and regulatory clarity are expected to sustain growth and improve cost control.

  • Q2 25/26

    H1 FY '26 saw 23% overall and 28% retail GWP growth, with PAT more than doubling year-over-year. GST reduction to 0% spurred over 50% retail growth in October, while combined and expense ratios improved. Group loss ratio rose due to mix, but retail remained stable.

  • Q1 25/26

    Q1 saw 28% YoY growth (32% in retail), with IFRS PAT nearly doubling to INR 70 crore and combined ratio improving to 103.2%. Loss ratios rose due to reserve increases and group mix, but expense ratios improved; volume growth drove premium gains. Key industry initiatives and tech upgrades support future outlook.

Fiscal Year 2025

  • Q4 24/25

    GWP grew 32% like-for-like to INR 7,406 crores, with IFRS PAT up 21% to INR 203.3 crores. Retail market share rose, group business expanded, and medical inflation was contained at 5%. Solvency and expense ratios improved, with strong digital and distribution growth.

  • Q3 24/25

    Q3 FY25 saw strong premium growth and improved profitability despite a major regulatory-driven accounting transition. Market share in retail health rose, technology adoption advanced, and expense ratios improved, with management confident in meeting future targets.

  • Q2 24/25

    Gross premium grew 36% year-over-year in H1 FY25, with market share gains and IFRS profit more than doubling. Technology and digital channels drove operational efficiency, while regulatory changes and price hikes present ongoing challenges.